Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
NEW YORK, May 5, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
Summary
GlobalData's new report, "Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017" provides key data, information and analysis on the global tumor markers market. The report provides market landscape, competitive landscape and market trends information on the tumor markers market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.
While tumor markers have been part of the global cancer diagnostics market since the 1960s, their popularity as therapeutic targets has only risen in the last few decades, primarily due to the increasing prevalence and mortality related to cancer. Cancer is currently the second leading cause of death in most developed countries of the world such as the US, the UK and so on, and is one of the most researched disease areas in the pharmaceutical and biotechnology industry. The global tumor markers market was estimated at $1 billion in 2010 and is expected to grow at a CAGR (compound annual growth rate) of over 6% till 2017. The tumor markers market is poised for rapid growth as researchers approach major technological breakthroughs in tumor diagnosis and therapy, the discovery of new specific antigens, and the genetic basis of cancer. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, the early detection of tumors, and monitoring biological responses to cancer therapy.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Annualized market revenues data from 2003 to 2010, forecast forward for 7 years to 2017. Company shares data for 2010.
- Qualitative analysis of key market trends, market drivers, and restraints by each category within tumor markers market.
- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
- Key players covered include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Fujirebio Inc., bioMerieux SA and Beckman Coulter.
Reasons to buy
- Develop business strategies by understanding the trends and developments that are driving the tumor markers market globally.
- Design and develop your product development, marketing and sales strategies.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What's the next big thing in the tumor markers market landscape? – Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the global tumor markers market and the factors shaping it.
1 Table of contents
1 Table of contents 3
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
2.1 GlobalData Report Guidance 11
3 Disease Overview: Cancer 12
3.1 Etiology 12
3.2 Types of cancers 12
3.2.1 Classification by Histology 12
3.2.2 Cancer Types by Site 13
3.3 Cancer Signs and Symptoms 14
3.4 Cancer Diagnosis 14
3.5 Epidemiology 15
4 Tumor Markers Overview 18
4.1 Tumor Markers: Technology Overview 18
4.1.1 Introduction 18
4.1.2 Types of Tumor Markers 18
4.1.3 Applications 18
5 Tumor Markers: Global Market Characterization 20
5.1 Tumor Markers Market, Global, Revenue ($m), Historic, 2003 ? 2010 20
5.2 Tumor Markers Market, Global, Revenue ($m), Forecast, 2010 ? 2017 21
5.3 Tumor Markers, Key Market Trends 22
5.3.1 Increasing Investments by Private Equity (PE) /Venture Capital (VC) Firms in Startups is Driving Innovation and Market Growth 22
5.3.2 Novel Tumor Markers Makes Diagnostic Test for Ovarian Cancer More Efficient 22
5.4 Tumor Markers, Market Dynamics 23
5.4.1 Market Drivers 23
5.4.2 Market Restraints 27
5.5 Tumor Markers Market, Opportunities and Unmet Needs 28
5.5.1 Opportunities: Highly Fragmented Market to Provide a Significant Opportunity for Big Tumor Marker Manufacturers 28
5.5.2 Unmet Needs 28
6 Tumor Markers Market, by Country, Revenue ($m), 2003 – 2017 29
6.1 Tumor Markers Market, The US, Revenue ($m), Historic, 2003–2010 29
6.2 Tumor Markers Market, The US, Revenue ($m), Forecast, 2010–2017 30
6.3 Tumor Markers Market, Canada, Revenue ($m), Historic, 2003–2010 31
6.4 Tumor Markers Market, Canada, Revenue ($m), Forecast, 2010–2017 32
6.5 Tumor Markers Market, The UK, Revenue ($m), Historic, 2003-2010 33
6.6 Tumor Markers Market, The UK, Revenue ($m), Forecast, 2010-2017 34
6.7 Tumor Markers Market, Germany, Revenue ($m), Historic, 2003-2010 35
6.8 Tumor Markers Market, Germany, Revenue ($m), Forecast, 2010-2017 36
6.9 Tumor Markers Market, France, Revenue ($m), Historic, 2003- 2010 37
6.10 Tumor Markers Market, France, Revenue ($m), Forecast, 2010-2017 38
6.11 Tumor Markers Market, Italy, Revenue ($m), Historic, 2003-2010 39
6.12 Tumor Markers Market, Italy, Revenue ($m), Forecast, 2010-2017 40
6.13 Tumor Markers Market, Spain, Revenue ($m), Historic, 2003-2010 41
6.14 Tumor Markers Market, Spain, Revenue ($m), Forecast, 2010-2017 42
6.15 Tumor Markers Market, Japan, Revenue ($m), Historic, 2003-2010 43
6.16 Tumor Markers Market, Japan, Revenue ($m), Forecast, 2010-2017 44
6.17 Tumor Markers Market, China, Revenue ($m), Historic, 2003-2010 45
6.18 Tumor Markers Market, China, Revenue ($m), Forecast, 2010-2017 46
6.19 Tumor Markers Market, India, Revenue ($m), Historic, 2003-2010 47
6.20 Tumor Markers Market, India, Revenue ($m), Forecast, 2010-2017 48
6.21 Tumor Markers Market, Australia, Revenue ($m), Historic, 2003-2010 49
6.22 Tumor Markers Market, Australia, Revenue ($m), Forecast, 2010-2017 50
6.23 Tumor Markers Market, Brazil, Revenue ($m), Historic, 2003-2010 51
6.24 Tumor Markers Market, Brazil, Revenue ($m), Forecast, 2010-2017 52
7 Tumor Markers Market: Competitive Landscape 53
7.1 Tumor Markers Market, Key Company Share (%), 2010 53
7.2 Abbott Laboratories (Abbott) 54
7.2.1 Company Overview 54
7.2.2 Marketed Products 54
7.2.3 Pipeline Products 54
7.2.4 SWOT Analysis 55
7.3 F. Hoffman-La Roche 57
7.3.1 Company Overview 57
7.3.2 Marketed Products 57
7.3.3 Pipeline Products 58
7.3.4 SWOT Analysis 58
7.4 Fujirebio Inc. 60
7.4.1 Company Overview 60
7.4.2 Marketed Products 60
7.4.3 SWOT Analysis 61
7.5 bioMerieux S.A. 62
7.5.1 Company Overview 62
7.5.2 Marketed Products 62
7.5.3 Pipeline Products 63
7.5.4 SWOT Analysis 63
7.6 Beckman Coulter 64
7.6.1 Company Overview 64
7.6.2 Marketed Products 64
7.6.3 Pipeline Products 64
7.6.4 SWOT Analysis 65
8 Global Tumor Markers Market: Other Major Companies 67
8.1 Clarient Inc. 67
8.1.1 Company Overview 67
8.1.2 Marketed Products 67
8.1.3 Pipeline Products 67
8.2 Siemens Healthcare 68
8.2.1 Company Overview 68
8.2.2 Marketed Products 68
8.2.3 Pipeline Products 68
8.3 DiaSorin SpA 69
8.3.1 Company Overview 69
8.3.2 Marketed Products 69
8.4 QIAGEN N.V. 70
8.4.1 Company Overview 70
8.4.2 Marketed Products 70
8.4.3 Pipeline Products 70
8.5 Xeptagen SpA 71
8.5.1 Company Overview 71
8.5.2 Marketed Products 71
8.5.3 Pipeline Products 71
9 Global Tumor Markers Market: Strategic Pipeline Assessment 72
9.1 Tumor Markers Market: Pipeline Products summary 72
9.2 Tumor Markers, Pipeline Products by Development Stage, Global, 2010 72
9.3 Tumor Markers Market, Pipeline Products by Therapy Area, Global, 2010 73
10 Tumor Markers- Important Pipeline Products by Company 74
10.1 F.Hoffman La Roche' 74
10.1.1 Integrated Modular Analytics cyfra21-1/NSE Test 74
10.2 bioMerieux S.A. 74
10.2.1 EHT Dx 12 74
10.2.2 EHT Dx 13 74
10.3 Siemens Healthcare 75
10.4 Epigenomics AG 75
10.4.1 Epi proColon-mSEPT9 75
10.4.2 Lung Cancer Screening Test 77
10.5 Xeptagen SpA 78
10.5.1 DCP-IgM Liver cancer Test 78
10.5.2 Multi-Marker biochip 79
10.5.3 SCCA–IgM Pulmonary cancer test 79
10.6 AdnaGen Inc. 79
10.6.1 AdnaTest BreastCancer 79
10.6.2 AdnaTest ColonCancer 83
10.7 QIAGEN N.V. 84
10.7.1 BRaf Test-Colon Cancer 84
10.7.2 EGFR Assay-Lung Cancer 84
10.8 Quanterix corporation 85
10.8.1 AccuPSA Test 85
10.9 Rosetta Genomics 85
10.9.1 miRNA Based Diagnostic Test For Breast Cancer 85
10.10 Oncomethylome Sciences 86
10.10.1 Cervical cancer diagnostic test 86
10.10.2 InformDx - Lung Cancer test 86
10.11 Onconome Inc. 87
10.11.1 ColoMark CCSA-4 Serum Assay 87
10.12 Source MDx 88
10.12.1 Aggressive Cancer Stratification–Prostate Cancer 88
10.12.2 Precision Profile-Prostate Cancer Early Detection 88
10.13 Trovagene, Inc. 89
10.13.1 AML/NPM1-Bone Marrow/Blood 89
10.14 Mitomics Inc. 89
10.14.1 Bladder Cancer-Diagnostic Test 89
10.15 Glycozyme. 89
10.15.1 Breast cancer Biomarker Assay 89
10.16 Neogenix Oncology Corporation 90
10.16.1 Diagnostic Marker-Colorectal Cancer 90
10.17 Exiqon A/S 92
10.17.1 Colon Cancer Recurrence Test 92
10.17.2 miRNA Test-Endometrial Cancer 92
10.18 China Sky One Medical, Inc. 93
10.18.1 Semi-quantitative test for uterine cancer 93
10.18.2 Liver Cancer Diagnostic Kit 93
10.19 Advanced Cell Diagnostics 93
10.19.1 Breast Cancer Test 93
10.20 Zetiq Technologies Ltd 94
10.20.1 CellDetect for Cervical Cancer 94
10.21 Biomoda, Inc. 94
10.21.1 Cypath-bladder cancer diagnostic assay 94
10.22 Predictive Biosciences. Inc. 95
10.22.1 Biomarker mGSTP1-Prostate Cancer 95
10.23 Power3 Medical Products, Inc 95
10.23.1 BC-SeraPro Assay 95
10.24 DiaGenic ASA 96
10.24.1 BCtect 96
10.24.2 Breast Cancer Screening Test 96
10.25 Protagen AG 97
10.25.1 Breast Cancer-Early Diagnosis assay 97
10.26 BioMarCare Technologies Ltd. 97
10.26.1 Breast PARpanel 97
10.27 Akers Biosciences, Inc. 97
10.27.1 Breath PulmoHealth Check 97
10.28 Allegro Diagnostics, Inc. 98
10.28.1 BronchoGen 98
10.29 MabCure, Inc. 99
10.29.1 Diagnostic Test-Breast Carcinoma 99
10.30 Cangen Biotechnologies, Inc. 99
10.30.1 Early Stage Lung Cancer Diagnostic test 99
10.31 Exosome Diagnostics, Inc. 100
10.31.1 EGFR Cancer Gene Mutation test 100
10.32 Exagen Diagnostics, Inc. 101
10.32.1 eXagenBC(ER/PR+) 101
10.33 Martell Biosystems, Inc 101
10.33.1 FACTT-Breast cancer assay 101
10.34 Miraculins Inc. 102
10.34.1 P2V Prostate Cancer Test 102
10.34.2 Gastric Cancer Diagnostic Test 103
10.35 NorDiag ASA 104
10.35.1 Genefec III 104
10.36 A&G Pharmaceutical, Inc. 105
10.36.1 GP88 Blood Diagnostic Test 105
10.37 Expression Pathology Inc. 105
10.37.1 HER2 Assay for Breast Cancer 105
10.38 Milagen, Inc 105
10.38.1 Immunoassay - Colon Cancer 105
10.39 IncellDx, Inc. 106
10.39.1 IncellDx Breast Cancer Test 106
10.40 Gene Express, Inc. 106
10.40.1 Lung Cancer Diagnostic Assay 106
10.41 GenomicTree Inc 106
10.41.1 MDScan Cervical Cancer Screening Test 106
10.42 BIOCRATES Life Sciences AG 107
10.42.1 Metabolomic Biomarker Assay-Cancer 107
10.43 Health Discovery Corporation 107
10.43.1 Molecular diagnostic test-pancreatic cancer 107
10.44 Gene Express, Inc. 107
10.44.1 Molecular Diagnostic Tests for Bladder Cancer 107
10.45 IRIS International, Inc. 110
10.45.1 NADiA ProsVue 110
10.46 Everist Genomics, Inc. 111
10.46.1 OncoDefender-CRC 111
10.47 Orion Genomics LLC 112
10.47.1 Orion Colorectal Cancer Risk Test 112
10.48 Correlogic Systems, Inc. 112
10.48.1 OvaCheck 112
10.49 Arrayit Corporation 112
10.49.1 OvaDx 112
10.50 Protagen AG 113
10.50.1 Ovarian Cancer-Early Diagnosis Assay 113
10.51 HealthLinx Limited 113
10.51.1 OvPlex 2nd Generation 113
10.52 Strategic Diagnostics Inc. 114
10.52.1 Pancreatic Cancer Assay 114
10.53 HistoRx, Inc. 115
10.53.1 PI3K Multimarker Assay 115
10.53.2 PROGENSA PCA3 Assay 115
10.54 Correlogic Systems, Inc. 118
10.54.1 ProstaCheck 118
10.55 AnalizaDx, LLC 118
10.55.1 Prostate Cancer Biomarker Test 118
10.56 Ambrilia Biopharma Inc. 119
10.56.1 PSP94 Immunoassay 119
10.57 BioCurex Inc 119
10.57.1 RECAF Blood Test 119
10.58 Fermiscan Holdings Limited 120
10.58.1 The Fermiscan Test 120
10.59 Nanosphere, Inc. 123
10.59.1 Verisens Ultra-Sensitive PSA Assay 123
11 Global Tumor Markers Market: Deals Landscape 124
11.1 Global Tumor Markers Market: Deals Overview 124
11.2 Global Tumor Markers Market: Key Acquisitions 124
11.2.1 Vivakor Enters Into Memorandum of Understanding to Merge with Resolution Biomedical 124
11.2.2 GE Healthcare Acquires Clarient 124
11.2.3 Danaher to Acquire Beckman Coulter Inc 125
11.2.4 Myriad Genetics to Acquire Novel Technology from Melanoma Diagnostics 125
11.2.5 Fujirebio Acquires Innogenetics from Abbott Laboratories 125
11.3 Global Tumor Markers Market: Partnership Deals 126
11.3.1 UCL Business Enters Into a Licensing Agreement with Becton Dickinson 126
11.3.2 Rosetta Genomics Enters Into an Agreement with Carmel Medical Center 126
11.3.3 Transgene Signs an Agreement with Beckman Coulter Inc 126
11.3.4 Neogenix Oncology Enters an Agreement with IRCCS San Raffaele Pisana 127
11.3.5 Vermillion Enters Into an Agreement with Quest Diagnostics 127
11.3.6 BioMerieux Enters into a Co-Development Agreement with Biocartis 127
11.3.7 Epigenomics Enters Into an Agreement with Pronto Diagnostics 128
11.3.8 Roche Enters into a Licensing agreement with QIAGEN 128
11.3.9 OvaGene Oncology Enters into Licensing Agreement with Bergen Teknologioverforing and Medinnova 128
11.3.10 bioMerieux Signs into a Co-development Agreement with GlaxoSmithKline 129
11.3.11 IDL Biotech Enters into a Licensing Agreement with Radim 129
11.3.12 Sysmex Europe Enters Into an Agreement with Adnagen 129
11.3.13 Immunogenetics Signs an Agreement with Adnagen 130
12 Appendix 131
12.1 Definition 131
12.2 Acronyms 132
12.3 Research Methodology 133
12.4 Secondary Research 133
12.5 Primary Research 133
12.6 Models 134
12.7 Forecasts 134
12.8 Expert Panels 134
12.9 GlobalData Consulting 134
12.10 Contact Us 135
12.11 Disclaimer 135
List of Tables
Table 1: Global Cancer Incidence, Most Common Cancers, by Sex, 2008 16
Table 2: Types of Tumor Markers 18
Table 3: Tumor Markers Market, Global, Revenue ($m), 2003 – 2010 20
Table 4: Tumor Markers Market, Global, Revenue ($m), 2010 – 2017 21
Table 5: Increase in Specificity and Sensitivity, Multi-Marker Tests 23
Table 6: Cancer Incidence, by Geography, (%), 2008 24
Table 7: Tumor Markers Market, The US, Revenue ($m), 2003-2010 29
Table 8: Tumor Markers Market, The US, Revenue ($m), 2010-2017 30
Table 9: Tumor Markers Market, Canada, Revenue ($m), 2003-2010 31
Table 10: Tumor Markers Market, Canada, Revenue ($m), 2010-2017 32
Table 11: Tumor Markers Market, The UK, Revenue ($m), 2003-2010 33
Table 12: Tumor Markers Market, The UK, Revenue ($m), 2010-2017 34
Table 13: Tumor Markers Market, Germany, Revenue ($m), 2003-2010 35
Table 14: Tumor Markers Market, Germany, Revenue ($m), 2010-2017 36
Table 15: Tumor Markers Market, France, Revenue ($m), 2003-2010 37
Table 16: Tumor Markers Market, France, Revenue ($m), 2010-2017 38
Table 17: Tumor Markers Market, Italy, Revenue ($m), 2003-2010 39
Table 18: Tumor Markers Market, Italy, Revenue ($m), 2010-2017 40
Table 19: Tumor Markers Market, Spain, Revenue ($m), 2003-2010 41
Table 20: Tumor Markers Market, Spain, Revenue ($m), 2010-2017 42
Table 21: Tumor Markers Market, Japan, Revenue ($m), 2003-2010 43
Table 22: Tumor Markers Market, Japan, Revenue ($m), 2010-2017 44
Table 23: Tumor Markers Market, China, Revenue ($m), 2003-2010 45
Table 24: Tumor Markers Market, China, Revenue ($m), 2010-2017 46
Table 25: Tumor Markers Market, India, Revenue ($m), 2003-2010 47
Table 26: Tumor Markers Market, India, Revenue ($m), 2010-2017 48
Table 27: Tumor Markers Market, Australia, Revenue ($m), 2003-2010 49
Table 28: Tumor Markers Market, Australia, Revenue ($m), 2010-2017 50
Table 29: Tumor Markers Market, Brazil, Revenue ($m), 2003-2010 51
Table 30: Tumor Markers Market, Brazil, Revenue ($m), 2010-2017 52
Table 31: Tumor Markers Market, Global, Company Revenue ($m), 2010 53
Table 32: Abbott, Tumor Markers, Marketed Products 54
Table 33: Abbott, Tumor Markers, Pipeline Products 54
Table 34: F. Hoffman La Roche, Tumor Markers, Pipeline Products 58
Table 35: Fujirebio, Tumor Markers, Marketed Products 60
Table 36: bioMerieux, Tumor Markers, Marketed Products 62
Table 37: Beckman Coulter, Tumor Markers, Marketed Products 64
Table 38: Clarient, Tumor Markers, Marketed Products 67
Table 39: Siemens Healthcare, Tumor Markers, Marketed Products 68
Table 40: DiaSorin, Tumor Markers, Marketed Products 69
Table 41: QIAGEN, Tumor Markers, Marketed Products 70
Table 42: QIAGEN, Tumor Markers, Pipeline Products 70
Table 43: Xeptagen, Tumor Markers, Marketed Products 71
Table 44: Xeptagen, Tumor Markers, Pipeline Products 71
Table 45: Epi proColon-mSEPT9 - Clinical Trial 75
Table 46: Epi proColon-mSEPT9 - Clinical Trial 76
Table 47: Lung Cancer Screening Test - Clinical Trial 77
Table 48: DCP-IgM Liver Cancer Test - Clinical Trial 78
Table 49: AdnaTest BreastCancer - Clinical Trial 80
Table 50: AdnaTest BreastCancer - Clinical Trial 81
Table 51: AdnaTest BreastCancer - Clinical Trial 82
Table 52: AdnaTest BreastCancer - Clinical Trial 83
Table 53: AdnaTest ColonCancer - Clinical Trial 84
Table 54: ColoMark CCSA-4 Serum Assay - Clinical Trial 87
Table 55: Precision Profile-Prostate Cancer Early Detection Clinical Trial 88
Table 56: Diagnostic Marker-Colorectal Cancer - Clinical Trial 90
Table 57: Diagnostic Marker-Colorectal Cancer - Clinical Trial 91
Table 58: Semi-Quantitative Test for Uterine Cancer - Clinical Trial 93
Table 59: Biomarker mGSTP1-Prostate Cancer - Clinical Trial 95
Table 60: BCtect - Breast Cancer - Clinical Trial 96
Table 61: BronchoGen - Clinical Trial 98
Table 62: Early Stage Lung Cancer Diagnostic test - Clinical Trial 100
Table 63: P2V Prostate Cancer Test - Clinical Trial 102
Table 64: P2V Prostate Cancer Test - Clinical Trial 102
Table 65: Gastric Cancer Diagnostic Test - Clinical Trial 103
Table 66: Genefec III - Clinical Trial 104
Table 67: Genefec III - Clinical Trial 104
Table 68: Molecular Diagnostic Tests For Bladder Cancer - Clinical Trial 108
Table 69: Molecular Diagnostic Tests For Bladder Cancer - Clinical Trial 109
Table 70: NADiA ProsVue - Clinical Trial 110
Table 71: OncoDefender-CRC - Clinical Trial 111
Table 72: OvPlex 2nd Generation - Clinical Trial 113
Table 73: OvPlex 2nd Generation - Clinical Trial 114
Table 74: PROGENSA PCA3 Assay - Clinical Trial 115
Table 75: PROGENSA PCA3 Assay - Clinical Trial 116
Table 76: PROGENSA PCA3 Assay - Clinical Trial 116
Table 77: PROGENSA PCA3 Assay - Clinical Trial 117
Table 78: ProstaCheck - Clinical Trial 118
Table 79: PSP94 Immunoassay - Clinical Trial 119
Table 80: The Fermiscan Test - Clinical Trial 120
Table 81: The Fermiscan Test - Clinical Trial 121
Table 82: The Fermiscan Test - Clinical Trial 122
Table 83: Verisens Ultra-Sensitive PSA Assay - Clinical Trial 123
List of Figures
Figure 1: Classification of Cancers, by Tissue of Origin 12
Figure 2: Most Common Types of Cancers, Classification by Primary Site of Origin 13
Figure 3: Cancer Incidence Rate, Global, 2008 15
Figure 4: Cancer Incidence, Global, Most Common Cancers, by Sex, 2008 16
Figure 5: List Of Common Tumor Markers Used for Detection of Multiple Cancers, 2010 19
Figure 6: Tumor Markers Market, Global, Revenue($m), 2003 – 2010 20
Figure 7: Tumor Markers Market, Global, Revenue ($m), 2010 – 2017 21
Figure 8: Tumor Markers, Market Dynamics 23
Figure 9: Cancer Incidence, by Geography, (%), 2008 24
Figure 10: Healthcare Spending Growth Rate (%), Asia-Pacific, 2007-2008 26
Figure 11: Tumor Markers Market, The US, Revenue ($m), 2003-2010 29
Figure 12: Tumor Markers Market, The US, Revenue ($m), 2010-2017 30
Figure 13: Tumor Markers Market, Canada, Revenue ($m), 2003-2010 31
Figure 14: Tumor Markers Market, Canada, Revenue ($m), 2010-2017 32
Figure 15: Tumor Markers Market, The UK, Revenue ($m), 2003-2010 33
Figure 16: Tumor Markers Market, The UK, Revenue ($m), 2010-2017 34
Figure 17: Tumor Markers Market, Germany, Revenue ($m), 2003-2010 35
Figure 18: Tumor Markers Market, Germany, Revenue ($m), 2010-2017 36
Figure 19: Tumor Markers Market, France, Revenue ($m), 2003-2010 37
Figure 20: Tumor Markers Market, France, Revenue ($m), 2010-2017 38
Figure 21: Tumor Markers Market, Italy, Revenue ($m), 2003-2010 39
Figure 22: Tumor Markers Market, Italy, Revenue ($m), 2010-2017 40
Figure 23: Tumor Markers Market, Spain, Revenue ($m), 2003-2010 41
Figure 24: Tumor Markers Market, Spain, Revenue ($m), 2010-2017 42
Figure 25: Tumor Markers Market, Japan, Revenue ($m), 2003-2010 43
Figure 26: Tumor Markers Market, Japan, Revenue ($m), 2010-2017 44
Figure 27: Tumor Markers Market, China, Revenue ($m), 2003-2010 45
Figure 28: Tumor Markers Market, China, Revenue ($m), 2010-2017 46
Figure 29: Tumor Markers Market, India, Revenue ($m), 2003-2010 47
Figure 30: Tumor Markers Market, India, Revenue ($m), 2010-2017 48
Figure 31: Tumor Markers Market, Australia, Revenue ($m), 2003-2010 49
Figure 32: Tumor Markers Market, Australia, Revenue ($m), 2010-2017 50
Figure 33: Tumor Markers Market, Brazil, Revenue ($m), 2003-2010 51
Figure 34: Tumor Markers Market, Brazil, Revenue ($m), 2010-2017 52
Figure 35: Tumor Markers Market, Global, Key Company Share (%), 2010 53
Figure 36: SWOT Analysis, Abbott 55
Figure 37: SWOT Analysis, F. Hoffman La Roche 58
Figure 38: SWOT Analysis, Fujirebio, Inc. 61
Figure 39: SWOT Analysis, bioMerieux SA 63
Figure 40: SWOT Analysis, Beckman Coulter 65
Figure 41: Tumor Markers, Pipeline Products by Development Stage, Global, 2010 72
Figure 42: Tumor Markers, Pipeline Products by Therapy Area, Global, 2010 73
Companies Mentioned
Abbott Laboratories (Abbott)
F. Hoffman-La Roche
Fujirebio Inc.
bioMerieux S.A.
Beckman Coulter
Clarient Inc.
Siemens Healthcare
DiaSorin SpA
QIAGEN N.V.
Xeptagen SpA
To order this report:
: Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article